Aurelius Omlin1, Oliver Sartor2, Christian Rothermundt3, Richard Cathomas4, Johann S De Bono5, Liji Shen6, Zhen Su6, Silke Gillessen3. 1. Kantonsspital St Gallen, Department of Oncology and Hematology, St Gallen, Switzerland. Electronic address: aurelius.omlin@kssg.ch. 2. Tulane University, Department of Medicine and Urology, New Orleans, LA. 3. Kantonsspital St Gallen, Department of Oncology and Hematology, St Gallen, Switzerland. 4. Division of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland. 5. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, ICR, Sutton, UK. 6. Sanofi-Aventis, Bridgewater, NJ.
Abstract
INTRODUCTION: We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel. MATERIALS AND METHODS: Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed. RESULTS: The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel. CONCLUSION: Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.
INTRODUCTION: We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel. MATERIALS AND METHODS: Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed. RESULTS: The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel. CONCLUSION: Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.
Authors: Alexander Pan; Rachel E Reingold; Jimmy L Zhao; Andrea Moy; Lukas Kraehenbuehl; George Dranitsaris; Sean M McBride; Howard I Scher; Marisa A Kollmeier; Han Xiao; Dana E Rathkopf; Mario E Lacouture Journal: J Urol Date: 2022-01-12 Impact factor: 7.600
Authors: Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar Journal: Lancet Date: 2015-12-21 Impact factor: 79.321
Authors: Giuseppe Di Lorenzo; Martina Pagliuca; Teresa Perillo; Alfonso Benincasa; Davide Bosso; Sabino De Placido; Carlo Buonerba Journal: Medicine (Baltimore) Date: 2016-04 Impact factor: 1.889
Authors: Alix F Leblanc; Jason A Sprowl; Paola Alberti; Alessia Chiorazzi; W David Arnold; Alice A Gibson; Kristen W Hong; Marissa S Pioso; Mingqing Chen; Kevin M Huang; Vamsi Chodisetty; Olivia Costa; Tatiana Florea; Peter de Bruijn; Ron H Mathijssen; Raquel E Reinbolt; Maryam B Lustberg; Lara E Sucheston-Campbell; Guido Cavaletti; Alex Sparreboom; Shuiying Hu Journal: J Clin Invest Date: 2018-01-16 Impact factor: 14.808
Authors: Jason T Anderson; Kevin M Huang; Maryam B Lustberg; Alex Sparreboom; Shuiying Hu Journal: Rev Physiol Biochem Pharmacol Date: 2022 Impact factor: 7.500